High Court Denies Bid To Review Neurontin RICO Rulings

Law360, New York (December 9, 2013, 12:47 PM EST) -- The U.S. Supreme Court on Monday denied Pfizer Inc.’s bid to rehear three First Circuit rulings related to its allegedly deceptive marketing of Neurontin, allowing to stand the First Circuit's determination that resulting off-label prescriptions harmed Kaiser Foundation Health Plan Inc. and others.

That ruling affirmed a $142 million jury verdict in favor of HMO operator Kaiser, and the high court's denial of certiorari means the company is now facing the possibility of two further trials against Aetna Inc. and Harden Manufacturing Corp. All three suits...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.